EOC Pharma Completes $71M Series C Financing

EOC Pharma Group ("EOC"), a leading oncology-focused development and commercialization company in China, has completed a Series C financing of nearly 500 million yuan (US$71 million), co-led by Tigermed and its affiliated funds, TF Capital and Yingke PE. Hanne Capital and Everest Venture Capital also participated in the round. Sinolife Asset serves as the exclusive financial advisor for this round.

Proceeds of this financing will mainly be used to advance the development of EOC's existing clinical pipeline.

EOC is a fast-growing biopharmaceutical company based in Shanghai,which is focused on the in-licensing of innovative global oncology products, and developing, manufacturing and commercializing them for the China market, especially for breast and stomach cancer. The company not only develops products at new targets, but also actively introduces clinical oncology products from overseas. The Company has a fully integrated manufacturing, development and commercialization platform, bringing potentially top-ranking new drugs for Chinese patients.

EOC has a number of clinical-stage products. EOC103, as a type of selective HDAC inhibitor, has entered into phase III breast cancer clinical trials and has been certificated as the "Breakthrough Therapy Designation" by FDA. EOC315 is a highly selective VEGFR inhibitor as the combination of oxaliplatin and capecitabine for the first-line treatment of advanced gastric cancer. EOC202 is a kind of LAG3 recombinant biologic used in combination with chemotherapy for breast cancer. EOC317 is a highly active FGFR inhibitor that can be used to treat FGFR mutations or gene proliferation in a variety of cancers such as gastric cancer and urothelial carcinoma.

As a leading Contract Research Organization (CRO) in China, Tigermed is dedicated to enabling its clients to market their products successfully all over the world. Since its inception in 2004, Tigermed has always used new technologies and partnerships to accelerate product development and generate clinical evidence for its clients.

Headquartered in Hangzhou, Tigermed operates 33 subsidiaries with 95 offices across China and 11 others across the globe. Up to now, the company has supported over 600 clients internationally in more than1500 clinical trials. 

TF Capital focuses on investment in the life sciences industry, including biotechnology, therapeutics & pharmaceuticals, drug delivery, medical device & instruments, and medical service, primarily investing in early-stage companies with high potential.  

Through strategic investments in various key areas and right partnerships, TF Capital hopes to capture opportunities in the rapidly expanding Chinese life sciences market.